{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:56:21Z","timestamp":1759452981384,"version":"build-2065373602"},"reference-count":157,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.blre.2021.100903","type":"journal-article","created":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T04:10:12Z","timestamp":1635480612000},"page":"100903","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Philadelphia chromosome-negative myeloproliferative neoplasms in younger adults: A critical discussion of unmet medical needs, with a focus on pregnancy"],"prefix":"10.1016","volume":"52","author":[{"given":"Emanuela","family":"Sant'Antonio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar","family":"Borsani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Camerini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cirino","family":"Botta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Allegra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Siragusa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2021.100903_bb0005","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","article-title":"Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms","volume":"129","author":"Vainchenker","year":"2017","journal-title":"Blood."},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2021.100903_bb0010","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S0049-3848(13)70011-2","article-title":"Management of pregnant women with myeloproliferative neoplasms","volume":"131","author":"Lavi","year":"2013","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2021.100903_bb0015","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1053\/j.seminhematol.2005.05.022","article-title":"Essential thrombocythemia","volume":"42","author":"Finazzi","year":"2005","journal-title":"Semin Hematol"},{"key":"10.1016\/j.blre.2021.100903_bb0020","first-page":"1477","article-title":"The management and outcome of 18 pregnancies in women with polycythemia vera","volume":"90","author":"Robinson","year":"2005","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2021.100903_bb0025","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/bjh.14289","article-title":"Pregnancy outcomes in myeloproliferative neoplasms: UK prospective cohort study","volume":"175","author":"Alimam","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100903_bb0030","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1080\/17474086.2018.1506325","article-title":"Contemporary management of patients with BCR-ABL1-negative myeloproliferative neoplasms during pregnancy","volume":"11","author":"Griesshammer","year":"2018","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.blre.2021.100903_bb0035","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/ajh.26008","article-title":"Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management","volume":"95","author":"Tefferi","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2021.100903_bb0040","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ajh.26050","article-title":"Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management","volume":"96","author":"Tefferi","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2021.100903_bb0045","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/bjh.14173","article-title":"Disease characteristics and outcomes in younger adults with primary and secondary myelofibrosis","volume":"175","author":"Beauverd","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100903_bb0050","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00277-017-3165-9","article-title":"Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms","volume":"97","author":"Boddu","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2021.100903_bb0055","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/leu.2015.87","article-title":"Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis","volume":"29","author":"Palandri","year":"2015","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2021.100903_bb0060","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.3109\/10428194.2012.759656","article-title":"Age-related differences in disease characteristics and clinical outcomes in polycythemia vera","volume":"54","author":"Stein","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2021.100903_bb0065","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1182\/blood-2011-08-371328","article-title":"Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome","volume":"119","author":"Giona","year":"2012","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100903_bb0070","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/blood-2012-01-407981","article-title":"Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early\/prefibrotic primary myelofibrosis","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100903_bb0075","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11739-010-0429-y","article-title":"Treatment outcome in a cohort of young patients with polycythemia vera","volume":"5","author":"Ruggeri","year":"2010","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.blre.2021.100903_bb0080","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00277-009-0758-y","article-title":"Clinical and hematological presentation of children and adolescents with polycythemia vera","volume":"88","author":"Cario","year":"2009","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2021.100903_bb0085","first-page":"13","article-title":"Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia","volume":"88","author":"Passamonti","year":"2003","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2021.100903_bb0090","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4065\/76.1.22","article-title":"A long-term retrospective study of young women with essential thrombocythemia","volume":"76","author":"Tefferi","year":"2001","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.blre.2021.100903_bb0095","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1034\/j.1600-0609.2001.066005324.x","article-title":"Myelofibrosis with myeloid metaplasia in adult individuals 30 years old or younger: presenting features, evolution and survival","volume":"66","author":"Cervantes","year":"2001","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2021.100903_bb0100","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3324\/haematol.2011.056721","article-title":"Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy","volume":"97","author":"Pemmaraju","year":"2012","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2021.100903_bb0105","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1002\/ajh.25270","article-title":"Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger","volume":"93","author":"Szuber","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2021.100903_bb0110","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/j.1538-7836.2007.02424.x","article-title":"Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders","volume":"5","author":"De Stefano","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2021.100903_bb0115","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1160\/TH08-04-0205","article-title":"The JAK2 V617F mutation in patients with cerebral venous thrombosis: a rebuttal","volume":"99","author":"De Stefano","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2021.100903_bb0120","first-page":"1","article-title":"Trends in fertility and mother\u2019s age at first birth among rural and metropolitan counties: United States","volume":"2018","author":"Ely","year":"2007","journal-title":"NCHS Data Brief"},{"key":"10.1016\/j.blre.2021.100903_bb0125","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.mayocp.2018.08.022","article-title":"3023 Mayo clinic patients with myeloproliferative neoplasms: risk-stratified comparison of survival and outcomes data among disease subgroups","volume":"94","author":"Szuber","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.blre.2021.100903_bb0130","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.12666","article-title":"Association of treatments for myeloproliferative neoplasms during pregnancy with birth rates and maternal outcomes: a systematic review and meta-analysis","volume":"2","author":"Maze","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.blre.2021.100903_bb0135","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/bjh.16453","article-title":"How we manage Philadelphia-negative myeloproliferative neoplasms in pregnancy","volume":"189","author":"Robinson","year":"2020","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.blre.2021.100903_bb0140","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/bjh.17626","article-title":"Pregnancy in patients with myelofibrosis: Mayo-Florence series of 24 pregnancies in 16 women","volume":"195","author":"Gangat","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100903_bb0145","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1182\/asheducation-2006.1.246","article-title":"Myeloproliferative disease in pregnancy and other management issues","author":"Barbui","year":"2006","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.blre.2021.100903_bb0150","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1097\/AOG.0000000000002900","article-title":"ACOG practice bulletin no. 200 summary: early pregnancy loss","volume":"132","year":"2018","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.blre.2021.100903_bb0155","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJM198812013192214","article-title":"Incidence of early loss of pregnancy","volume":"319","author":"Hertz-Picciotto","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2021.100903_bb0160","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/AOG.0000000000004480","article-title":"Prediction and prevention of spontaneous preterm birth: ACOG practice bulletin summary, number 234","volume":"138","year":"2021","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.blre.2021.100903_bb0165","doi-asserted-by":"crossref","first-page":"697","DOI":"10.7326\/0003-4819-143-10-200511150-00006","article-title":"Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study","volume":"143","author":"Heit","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.blre.2021.100903_bb0170","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.ajog.2005.11.008","article-title":"Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality","volume":"194","author":"James","year":"2006","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.blre.2021.100903_bb0175","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1538-7836.2008.02961.x","article-title":"Ante- and postnatal risk factors of venous thrombosis: a hospital-based case-control study","volume":"6","author":"Jacobsen","year":"2008","journal-title":"J Thromb Haemost"},{"author":"Centers for Disease Control and Prevention","key":"10.1016\/j.blre.2021.100903_bb0180"},{"key":"10.1016\/j.blre.2021.100903_bb0185","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1136\/bmj.320.7251.1708","article-title":"Maternal age and fetal loss: population based register linkage study","volume":"320","author":"Nybo Andersen","year":"2000","journal-title":"BMJ."},{"key":"10.1016\/j.blre.2021.100903_bb0190","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1182\/blood-2016-09-728006","article-title":"Risk of venous thromboembolism in pregnant women with essential thrombocythemia: a systematic review and meta-analysis","volume":"129","author":"Skeith","year":"2017","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100903_bb0195","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1001\/jama.2017.3439","article-title":"Screening for preeclampsia: US preventive services task force recommendation statement","volume":"317","author":"Bibbins-Domingo","year":"2017","journal-title":"JAMA."},{"key":"10.1016\/j.blre.2021.100903_bb0200","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2011-000101","article-title":"Population-based trends in pregnancy hypertension and pre-eclampsia: an international comparative study","volume":"1","author":"Roberts","year":"2011","journal-title":"BMJ Open"},{"key":"10.1016\/j.blre.2021.100903_bb0205","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/ejh.12788","article-title":"Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway","volume":"98","author":"Roaldsnes","year":"2017","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2021.100903_bb0210","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/leu.2012.12","article-title":"How to manage children and young adults with myeloproliferative neoplasms","volume":"26","author":"Barbui","year":"2012","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2021.100903_bb0215","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/sj.leu.2404693","article-title":"Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients","volume":"21","author":"Alvarez-Larran","year":"2007","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2021.100903_bb0220","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.3324\/haematol.2018.200832","article-title":"Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review","volume":"104","author":"Ianotto","year":"2019","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2021.100903_bb0225","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/ejh.13232","article-title":"Characteristics and outcomes of young adults with Philadelphia-negative myeloproliferative neoplasms","volume":"102","author":"Barzilai","year":"2019","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2021.100903_bb0230","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.thromres.2014.03.040","article-title":"Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases","volume":"134","author":"Dentali","year":"2014","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2021.100903_bb0235","doi-asserted-by":"crossref","first-page":"E200","DOI":"10.1002\/ajh.23809","article-title":"Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms. An European leukemia net study","volume":"89","author":"Martinelli","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2021.100903_bb0240","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/ajh.25677","article-title":"Splanchnic vein thromboses associated with myeloproliferative neoplasms: an international, retrospective study on 518 cases","volume":"95","author":"Sant\u2019Antonio","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2021.100903_bb0245","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jhep.2012.07.034","article-title":"Pregnancy in women with portal vein thrombosis: results of a multicentric European study on maternal and fetal management and outcome","volume":"57","author":"Hoekstra","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.blre.2021.100903_bb0250","first-page":"984271","article-title":"Pregnancy in the setting of asymptomatic non-cirrhotic chronic portal vein thrombosis complicated by pre-eclampsia","volume":"2013","author":"Ustuner","year":"2013","journal-title":"Case Rep Obstet Gynecol"},{"key":"10.1016\/j.blre.2021.100903_bb0255","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0002-9343(96)00351-8","article-title":"Inapparent polycythemia vera: an unrecognized diagnosis","volume":"102","author":"Lamy","year":"1997","journal-title":"Am J Med"},{"key":"10.1016\/j.blre.2021.100903_bb0260","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1365-2141.2005.05490.x","article-title":"Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis","volume":"129","author":"Chait","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100903_bb0265","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2014-205663","article-title":"Elevated serum erythropoietin in a patient with polycythaemia vera presenting with Budd-Chiari syndrome","volume":"2014","author":"Jones","year":"2014","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.blre.2021.100903_bb0270","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1538-7836.2009.03303.x","article-title":"JAK2V617F mutation in patients with arterial thrombosis in the absence of overt myeloproliferative disease","volume":"7","author":"Dentali","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2021.100903_bb0275","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1016\/j.thromres.2013.07.014","article-title":"Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: a role for the JAK2 V617F mutation re-evaluation","volume":"132","author":"Colaizzo","year":"2013","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2021.100903_bb0280","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.thromres.2011.03.024","article-title":"Sex modulation of the occurrence of jak2 v617f mutation in patients with splanchnic venous thrombosis","volume":"128","author":"Colaizzo","year":"2011","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2021.100903_bb0285","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1182\/blood.2020008109","article-title":"The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms","volume":"137","author":"Hasselbalch","year":"2021","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100903_bb0290","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/bjh.14958","article-title":"Distinct clinical, laboratory and molecular features of myeloproliferative neoplasm patients with splanchnic vein thrombosis","volume":"183","author":"How","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100903_bb0295","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1160\/th15-04-0326","article-title":"Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment","volume":"115","author":"De Stefano","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2021.100903_bb0300","doi-asserted-by":"crossref","first-page":"E61","DOI":"10.1002\/ajh.24993","article-title":"Splanchnic vein thrombosis in patients with myeloproliferative neoplasms: the Mayo clinic experience with 84 consecutive cases","volume":"93","author":"Lavu","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2021.100903_bb0305","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.ejim.2018.03.009","article-title":"Heterogeneity among splanchnic vein thrombosis associated with myeloproliferative neoplasms","volume":"52","author":"Cattaneo","year":"2018","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.blre.2021.100903_bb0310","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.103","article-title":"Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients","volume":"6","author":"De Stefano","year":"2016","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2021.100903_bb0315","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1182\/blood-2011-09-376517","article-title":"Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis","volume":"120","author":"Smalberg","year":"2012","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100903_bb0320","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.leukres.2015.03.009","article-title":"Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis","volume":"39","author":"Gianelli","year":"2015","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2021.100903_bb0325","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-018-0054-y","article-title":"The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion","volume":"8","author":"Barbui","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2021.100903_bb0330","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.thromres.2018.05.007","article-title":"Prevalence of CALR mutations in splanchnic vein thrombosis: a systematic review and meta-analysis","volume":"167","author":"Li","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2021.100903_bb0335","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjh.13121","article-title":"Incidence of CALR mutations in patients with splanchnic vein thrombosis","volume":"168","author":"Haslam","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100903_bb0340","doi-asserted-by":"crossref","first-page":"4922","DOI":"10.1182\/blood-2007-11-125328","article-title":"The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases","volume":"111","author":"Kiladjian","year":"2008","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100903_bb0345","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/bjh.13235","article-title":"Detection of the CALR mutation in the diagnosis of splanchnic vein thrombosis","volume":"169","author":"Roques","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100903_bb0350","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1160\/TH14-12-1055","article-title":"Clinical utility of screening for CALR gene exon 9 mutations in patients with splanchnic venous thrombosis","volume":"113","author":"Colaizzo","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2021.100903_bb0355","first-page":"5702983","article-title":"Pregnancy in a woman with latent myeloproliferative neoplasm induced chronic portal vein thrombosis, portal cavernoma, and gastric varices","volume":"2019","author":"Durivage","year":"2019","journal-title":"Case Rep Obstet Gynecol"},{"key":"10.1016\/j.blre.2021.100903_bb0360","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.3324\/haematol.2015.139691","article-title":"Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series","volume":"101","author":"Beauverd","year":"2016","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2021.100903_bb0365","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1111\/j.1538-7836.2012.04719.x","article-title":"The JAK2 V617F mutation in patients with cerebral venous thrombosis","volume":"10","author":"Passamonti","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2021.100903_bb0370","doi-asserted-by":"crossref","first-page":"5617","DOI":"10.1182\/blood-2008-12-196014","article-title":"JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis","volume":"113","author":"Dentali","year":"2009","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100903_bb0375","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.beha.2012.07.003","article-title":"Extra-abdominal venous thromboses at unusual sites","volume":"25","author":"Martinelli","year":"2012","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.blre.2021.100903_bb0380","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41408-018-0101-8","article-title":"Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms","volume":"8","author":"De Stefano","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2021.100903_bb0385","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1182\/bloodadvances.2020003628","article-title":"A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms","volume":"5","author":"Hamulyak","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2021.100903_bb0390","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S1470-2045(04)01466-4","article-title":"Use of chemotherapy during human pregnancy","volume":"5","author":"Cardonick","year":"2004","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2021.100903_bb0395","first-page":"215","article-title":"Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation","volume":"89","author":"Barbui","year":"2004","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2021.100903_bb0400","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1365-2141.2005.05400.x","article-title":"Pregnancy and its management in the Philadelphia negative myeloproliferative diseases","volume":"129","author":"Harrison","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100903_bb0405","doi-asserted-by":"crossref","first-page":"S745","DOI":"10.1016\/j.ajog.2017.11.577","article-title":"Pathophysiology of placental-derived fetal growth restriction","volume":"218","author":"Burton","year":"2018","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.blre.2021.100903_bb0410","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1055\/a-1184-8388","article-title":"Understanding and preventing placenta-mediated pregnancy complications","volume":"40","author":"Skeith","year":"2020","journal-title":"Hamostaseologie."},{"key":"10.1016\/j.blre.2021.100903_bb0415","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.placenta.2020.06.004","article-title":"Placental infarcts in the collaborative perinatal project: variable associations infer variable constructs","volume":"99","author":"Misra","year":"2020","journal-title":"Placenta."},{"key":"10.1016\/j.blre.2021.100903_bb0420","doi-asserted-by":"crossref","first-page":"28418","DOI":"10.3390\/ijms161226104","article-title":"Thrombophilia and pregnancy complications","volume":"16","author":"Simcox","year":"2015","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.blre.2021.100903_bb0425","doi-asserted-by":"crossref","first-page":"E316","DOI":"10.1002\/ajh.25964","article-title":"Frequency and severity of pregnancy complications in women with hereditary thrombotic thrombocytopenic purpura","volume":"95","author":"Kasht","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2021.100903_bb0430","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1093\/rheumatology\/keaa499","article-title":"Maternal and foetal placental vascular malperfusion in pregnancies with anti-phospholipid antibodies","volume":"60","author":"Spinillo","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.blre.2021.100903_bb0435","doi-asserted-by":"crossref","first-page":"465","DOI":"10.47162\/RJME.61.2.16","article-title":"Evaluation of placental vascularization in thrombophilia and intrauterine growth restriction (IUGR)","volume":"61","author":"Voicu","year":"2020","journal-title":"Rom J Morphol Embryol"},{"key":"10.1016\/j.blre.2021.100903_bb0440","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/ajh.2830250316","article-title":"Essential thrombocythemia associated with recurrent abortions and fetal growth retardation","volume":"25","author":"Falconer","year":"1987","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2021.100903_bb0445","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0002-9378(88)90507-8","article-title":"Primary thrombocythemia in pregnancy: a report of two cases","volume":"159","author":"Mercer","year":"1988","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.blre.2021.100903_bb0450","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1034\/j.1600-0609.2000.90214.x","article-title":"Pregnancy in essential thrombocythaemia: treatment and outcome of 17 pregnancies","volume":"65","author":"Bangerter","year":"2000","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2021.100903_bb0455","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/14767058.2018.1484097","article-title":"Management and outcomes of 27 pregnancies in women with myeloproliferative neoplasms","volume":"33","author":"Lapoirie","year":"2020","journal-title":"J Matern Fetal Neonatal Med"},{"key":"10.1016\/j.blre.2021.100903_bb0460","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.2169\/internalmedicine.1311-18","article-title":"Multiple placental infarcts in a pregnant woman with essential thrombocythemia","volume":"57","author":"Edahiro","year":"2018","journal-title":"Intern Med"},{"issue":"3","key":"10.1016\/j.blre.2021.100903_bb0465","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s11899-021-00630-8","article-title":"Novel pathophysiological mechanisms of thrombosis in myeloproliferative neoplasms","volume":"16","author":"Reeves","year":"2021","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.blre.2021.100903_bb0470","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1055\/s-0034-1370794","article-title":"Thrombosis in myeloproliferative neoplasms","volume":"40","author":"Falanga","year":"2014","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2021.100903_bb0475","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/art.41191","article-title":"2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases","volume":"72","author":"Sammaritano","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.blre.2021.100903_bb0480","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1182\/blood-2007-01-071068","article-title":"Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation","volume":"110","author":"Passamonti","year":"2007","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100903_bb0485","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/ajh.21504","article-title":"Outcome of 122 pregnancies in essential thrombocythemia patients: a report from the Italian registry","volume":"84","author":"Melillo","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2021.100903_bb0490","doi-asserted-by":"crossref","first-page":"e443","DOI":"10.3324\/haematol.2015.131458","article-title":"Impact of mutational status on pregnancy outcome in patients with essential thrombocytemia","volume":"100","author":"Rumi","year":"2015","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2021.100903_bb0495","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1182\/blood.2019001318","article-title":"From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms","volume":"134","author":"Stein","year":"2019","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100903_bb0500","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/j.1600-0609.2009.01214.x","article-title":"Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies","volume":"82","author":"Gangat","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2021.100903_bb0505","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ajh.23635","article-title":"Pregnancy complications predict thrombotic events in young women with essential thrombocythemia","volume":"89","author":"Randi","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2021.100903_bb0510","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2021.100903_bb0515","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.blre.2008.03.007","article-title":"Management of Philadelphia negative chronic myeloproliferative disorders in pregnancy","volume":"22","author":"Griesshammer","year":"2008","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2021.100903_bb0520","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2141.2010.08122.x","article-title":"Guideline for investigation and management of adults and children presenting with a thrombocytosis","volume":"149","author":"Harrison","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100903_bb0525","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/ajh.2830460312","article-title":"Familial myeloproliferative syndrome","volume":"46","author":"P\u00e9rez-Encinas","year":"1994","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2021.100903_bb0530","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/tera.1420070207","article-title":"Postnatal effects in rats of prenatal treatment with hydroxyurea","volume":"7","author":"Butcher","year":"1973","journal-title":"Teratology."},{"key":"10.1016\/j.blre.2021.100903_bb0535","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/tera.1420110205","article-title":"Comparative distribution and embryotoxicity of hydroxyurea in pregnant rats and rhesus monkeys","volume":"11","author":"Wilson","year":"1975","journal-title":"Teratology."},{"key":"10.1016\/j.blre.2021.100903_bb0540","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/978-3-642-67729-8_49","article-title":"Hydroxyurea as a reference standard in teratological screening. Comparison of the embryotoxic and teratogenic effects following single intraperitoneal or repeated oral administrations to pregnant rats","volume":"4","author":"Aliverti","year":"1980","journal-title":"Arch Toxicol Suppl"},{"key":"10.1016\/j.blre.2021.100903_bb0545","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1248\/bpb1978.6.836","article-title":"Limb deformity induced in chick embryo by hydroxyurea","volume":"6","author":"Iwama","year":"1983","journal-title":"J Pharmacobiodyn"},{"key":"10.1016\/j.blre.2021.100903_bb0555","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1034\/j.1600-0609.2001.00367.x","article-title":"A single institutional experience with 43 pregnancies in essential thrombocythemia","volume":"66","author":"Wright","year":"2001","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2021.100903_bb0560","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3324\/haematol.2017.174672","article-title":"Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the evaluation of Anagrelide efficacy and long-term safety study","volume":"103","author":"Birgeg\u00e5rd","year":"2018","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2021.100903_bb0565","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bjh.16462","article-title":"Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts","volume":"189","author":"Al-Ali","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100903_bb0570","first-page":"1","article-title":"Management of hydroxyurea resistant or intolerant polycythemia vera","author":"Raman","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2021.100903_bb0585","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1038\/s41598-021-83222-z","article-title":"Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and improves learning and memory in adult mice","volume":"11","author":"Lee","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.blre.2021.100903_bb0590","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s00432-020-03430-4","article-title":"Interferon alpha for essential thrombocythemia during 34 high-risk pregnancies: outcome and safety","volume":"147","author":"Schrickel","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.blre.2021.100903_bb0595","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s12185-020-03001-w","article-title":"Interferon therapy for pregnant patients with essential thrombocythemia in Japan","volume":"113","author":"Edahiro","year":"2021","journal-title":"Int J Hematol"},{"key":"10.1016\/j.blre.2021.100903_bb0600","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1159\/000506447","article-title":"Outcome of pregnancy in the era of pegylated interferon alpha 2a in females with essential thrombocythemia: an experience from Qatar","volume":"13","author":"Abu-Tineh","year":"2020","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.blre.2021.100903_bb0610","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2021.100903_bb0615","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00277-016-2826-4","article-title":"Management of extreme thrombocytosis in myeloproliferative neoplasms: an international physician survey","volume":"96","author":"Koren-Michowitz","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2021.100903_bb0620","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1182\/blood-2006-05-025544","article-title":"Management of extreme thrombocytosis in otherwise low-risk essential thrombocythemia; does number matter?","volume":"108","author":"Tefferi","year":"2006","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100903_bb0625","doi-asserted-by":"crossref","first-page":"E182","DOI":"10.1002\/ajh.26137","article-title":"Extreme thrombocytosis in low-risk essential thrombocythemia: retrospective review of vascular events and treatment strategies","volume":"96","author":"Tefferi","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2021.100903_bb0630","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1802897","article-title":"Platelet counts during pregnancy","volume":"379","author":"Reese","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2021.100903_bb0635","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s00432-020-03430-4","article-title":"Interferon alpha for essential thrombocythemia during 34 high-risk pregnancies: outcome and safety","volume":"147","author":"Schrickel","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.blre.2021.100903_bb0640","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100903_bb0645","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","article-title":"Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia","volume":"123","author":"Rotunno","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100903_bb0650","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41408-020-0289-2","article-title":"Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis","volume":"10","author":"Guglielmelli","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2021.100903_bb0655","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1182\/blood-2009-08-238956","article-title":"Thrombosis in primary myelofibrosis: incidence and risk factors","volume":"115","author":"Barbui","year":"2010","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100903_bb0660","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2021.100903_bb0665","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2021.100903_bb0670","doi-asserted-by":"crossref","first-page":"106459","DOI":"10.1016\/j.leukres.2020.106459","article-title":"Pregnancy outcomes, risk factors, and cell count trends in pregnant women with essential thrombocythemia","volume":"98","author":"How","year":"2020","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2021.100903_bb0675","doi-asserted-by":"crossref","first-page":"e658","DOI":"10.1016\/S2352-3026(21)00204-0","article-title":"Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet","volume":"8","author":"Alvarez-Larran","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2021.100903_bb0680","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2010-01-263319","article-title":"Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia","volume":"116","author":"Alvarez-Larran","year":"2010","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100903_bb0685","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3324\/haematol.2016.146654","article-title":"Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation","volume":"101","author":"Alvarez-Larran","year":"2016","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2021.100903_bb0690","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1053\/j.seminhematol.2005.11.003","article-title":"Acquired von Willebrand syndrome: an underdiagnosed and misdiagnosed bleeding complication in patients with lymphoproliferative and myeloproliferative disorders","volume":"43","author":"Federici","year":"2006","journal-title":"Semin Hematol"},{"key":"10.1016\/j.blre.2021.100903_bb0695","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/jth.12967","article-title":"Qualitative and quantitative modifications of von Willebrand factor in patients with essential thrombocythemia and controlled platelet count","volume":"13","author":"Lancellotti","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2021.100903_bb0700","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1182\/blood.V82.6.1749.1749","article-title":"Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma","volume":"82","author":"Budde","year":"1993","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100903_bb0705","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1046\/j.1365-2141.1996.d01-1729.x","article-title":"The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count","volume":"93","author":"van Genderen","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100903_bb0710","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1046\/j.1365-2141.1997.4823285.x","article-title":"Decreased half-life time of plasma von Willebrand factor collagen binding activity in essential thrombocythaemia: normalization after cytoreduction of the increased platelet count","volume":"99","author":"van Genderen","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100903_bb0715","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood-2012-04-424911","article-title":"Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort","volume":"120","author":"Campbell","year":"2012","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100903_bb0720","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/leu.2011.258","article-title":"Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria","volume":"26","author":"Finazzi","year":"2012","journal-title":"Leukemia."},{"issue":"4","key":"10.1016\/j.blre.2021.100903_bb0725","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/hon.2903","article-title":"Acquired von Willebrand syndrome in myeloproliferative neoplasms with extreme thrombocytosis","volume":"39","author":"Trotti","year":"2021","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.blre.2021.100903_bb0730","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1365-2141.2011.08858.x","article-title":"Bleeding in essential thrombocythaemia: a retrospective analysis on 565 patients","volume":"156","author":"Palandri","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100903_bb0735","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2141.1986.tb07497.x","article-title":"Abnormalities of von Willebrand factor in myeloproliferative disease: a relationship with bleeding diathesis","volume":"63","author":"Fabris","year":"1986","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100903_bb0740","first-page":"264","article-title":"Acquired von Willebrand factor abnormalities in myeloproliferative disorders and other hematologic diseases: a retrospective analysis by a single institution","volume":"87","author":"S\u00e1nchez-Luceros","year":"2002","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2021.100903_bb0745","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejim.2016.11.011","article-title":"Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera","volume":"41","author":"Rottenstreich","year":"2017","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.blre.2021.100903_bb0750","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s11239-018-1663-9","article-title":"The course of acquired von Willebrand syndrome during pregnancy among patients with essential thrombocytosis","volume":"46","author":"Rottenstreich","year":"2018","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.blre.2021.100903_bb0755","first-page":"6633790","article-title":"Marked rebound of platelet count in the early postpartum period in a patient with essential thrombocythemia","volume":"2021","author":"Hashimoto","year":"2021","journal-title":"Case Rep Hematol"},{"key":"10.1016\/j.blre.2021.100903_bb0760","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/j.jacc.2020.06.090","article-title":"Venous thromboembolism associated with pregnancy: JACC focus seminar","volume":"76","author":"Nichols","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.blre.2021.100903_bb0765","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1600-0609.1997.tb00736.x","article-title":"Postpartum thrombosis in primary thrombocythaemia","volume":"59","author":"Willoughby","year":"1997","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2021.100903_bb0770","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/bjh.13605","article-title":"How we diagnose and treat essential thrombocythaemia","volume":"171","author":"Alimam","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100903_bb0775","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2021.100903_bb0780","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3109\/10428199609074361","article-title":"Essential thrombocythemia and pregnancy","volume":"22","author":"Griesshammer","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2021.100903_bb0785","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/archinte.1995.00430110137015","article-title":"Outcome analysis of 34 pregnancies in women with essential thrombocythemia","volume":"155","author":"Beressi","year":"1995","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.blre.2021.100903_bb0790","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/(SICI)1096-8652(199609)53:1<6::AID-AJH2>3.0.CO;2-V","article-title":"Primary thrombocythemia and pregnancy: treatment and outcome in fifteen cases","volume":"53","author":"Pagliaro","year":"1996","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2021.100903_bb0795","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1479-828X.2000.tb03163.x","article-title":"Management of essential thrombocythaemia during pregnancy","volume":"40","author":"Cincotta","year":"2000","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"10.1016\/j.blre.2021.100903_bb0800","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/ajh.10068","article-title":"Pregnancy and abortion in women with essential thrombocythemia","volume":"69","author":"Candoni","year":"2002","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2021.100903_bb0805","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1600-0609.2004.00324.x","article-title":"Pregnancy in essential thrombocythaemia: experience with 40 pregnancies","volume":"73","author":"Niittyvuopio","year":"2004","journal-title":"Eur J Haematol"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X21001090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X21001090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:26:23Z","timestamp":1759436783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X21001090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":157,"alternative-id":["S0268960X21001090"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2021.100903","relation":{},"ISSN":["0268-960X"],"issn-type":[{"type":"print","value":"0268-960X"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Philadelphia chromosome-negative myeloproliferative neoplasms in younger adults: A critical discussion of unmet medical needs, with a focus on pregnancy","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2021.100903","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100903"}}